Previous close | 96.00 |
Open | 96.28 |
Bid | 99.73 x 900 |
Ask | 100.02 x 900 |
Day's range | 95.39 - 102.95 |
52-week range | 49.19 - 103.66 |
Volume | |
Avg. volume | 509,409 |
Market cap | 4.964B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.78 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 106.55 |
Glaukos (GKOS) delivered earnings and revenue surprises of -20.69% and 8.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Comprehensive Analysis of Glaukos Corp's Latest Financial Performance
ALISO VIEJO, Calif., May 01, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: